secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000950170-24-051383
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics CEO and COO exit; merger portfolio prioritizes ADC and GA over other programs
--------------------------------------------------------------------------------

- Rachelle Jacques stepped down as CEO effective May 1; COO Melissa Bradford-Klug terminated without cause same date.
- Board member Samir Patel appointed interim CEO; compensated $50k monthly in RSUs.
- Interim CFO DiCicco gets $40k/month, 45% bonus, transaction bonus, and 1% RSU grant.
- Merger with Peak Bio to focus on ADC platform (TROP-2) and PAS-nomacopan for Geographic Atrophy.
- HSCT-TMA program suspended, PHP 303 discontinued; merger expected close Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/0000950170-24-051383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/aktx-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer